Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2024

Open Access 01-12-2024 | Review

A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle

Authors: Bolin Wang, Jinli Pei, Shengnan Xu, Jie Liu, Jinming Yu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2024

Login to get access

Abstract

Glutamine metabolism plays a pivotal role in cancer progression, immune cell function, and the modulation of the tumor microenvironment. Dysregulated glutamine metabolism has been implicated in cancer development and immune responses, supported by mounting evidence. Cancer cells heavily rely on glutamine as a critical nutrient for survival and proliferation, while immune cells require glutamine for activation and proliferation during immune reactions. This metabolic competition creates a dynamic tug-of-war between cancer and immune cells. Targeting glutamine transporters and downstream enzymes involved in glutamine metabolism holds significant promise in enhancing anti-tumor immunity. A comprehensive understanding of the intricate molecular mechanisms underlying this interplay is crucial for developing innovative therapeutic approaches that improve anti-tumor immunity and patient outcomes. In this review, we provide a comprehensive overview of recent advances in unraveling the tug-of-war of glutamine metabolism between cancer and immune cells and explore potential applications of basic science discoveries in the clinical setting. Further investigations into the regulation of glutamine metabolism in cancer and immune cells are expected to yield valuable insights, paving the way for future therapeutic interventions.
Literature
1.
Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21(2):141–62.PubMedCrossRef
2.
Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011;11(5):325–37.PubMedCrossRef
3.
Pantel AR, Ackerman D, Lee SC, Mankoff DA, Gade TP. Imaging cancer metabolism: underlying biology and emerging strategies. J Nucl Med. 2018;59(9):1340–9.PubMedPubMedCentralCrossRef
4.
Reinfeld BI, Madden MZ, Wolf MM, Chytil A, Bader JE, Patterson AR, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021;593(7858):282–8.PubMedPubMedCentralCrossRef
5.
Fu Q, Xu L, Wang Y, Jiang Q, Liu Z, Zhang J, et al. Tumor-associated macrophage-derived interleukin-23 interlinks kidney cancer glutamine addiction with immune evasion. Eur Urol. 2019;75(5):752–63.PubMedCrossRef
6.
Kerk SA, Lin L, Myers AL, Sutton DJ, Andren A, Sajjakulnukit P, et al. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Elife. 2022;11:e73245.PubMedPubMedCentralCrossRef
7.
Guo C, You Z, Shi H, Sun Y, Du X, Palacios G, et al. SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity. Nature. 2023;620(7972):200–8.PubMedPubMedCentralCrossRef
8.
9.
Krebs HA. Metabolism of amino-acids: the synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. Biochem J. 1935;29(8):1951–69.PubMedPubMedCentralCrossRef
10.
Kovacevic Z, Morris HP. The role of glutamine in the oxidative metabolism of malignant cells. Cancer Res. 1972;32(2):326–33.PubMed
11.
Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem. 1979;254(8):2669–76.PubMedCrossRef
12.
13.
Lobo C, Ruiz-Bellido MA, Aledo JC, Marquez J, Nunez De Castro I, Alonso FJ. Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. Biochem J. 2000;348 Pt 2(Pt 2):257–61.
14.
Gross MI, Demo SD, Dennison JB, Chen L, Chernov-Rogan T, Goyal B, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014;13(4):890–901.PubMedCrossRef
15.
Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, et al. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion. Science. 2019;366(6468):1013–21.PubMedPubMedCentralCrossRef
16.
17.
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(11):749.PubMedCrossRef
18.
19.
20.
21.
Ma G, Zhang Z, Li P, Zhang Z, Zeng M, Liang Z, et al. Reprogramming of glutamine metabolism and its impact on immune response in the tumor microenvironment. Cell Commun Signal. 2022;20(1):114.PubMedPubMedCentralCrossRef
22.
Pallett LJ, Dimeloe S, Sinclair LV, Byrne AJ, Schurich A. A glutamine “tug-of-war”: targets to manipulate glutamine metabolism for cancer immunotherapy. Immunother Adv. 2021;1(1):ltab010.PubMedPubMedCentralCrossRef
23.
Zhu L, Zhu X, Wu Y. Effects of glucose metabolism, lipid metabolism, and glutamine metabolism on tumor microenvironment and clinical implications. Biomolecules. 2022;12(4):580.PubMedPubMedCentralCrossRef
24.
Sharma S, Agnihotri N, Kumar S. Targeting fuel pocket of cancer cell metabolism: a focus on glutaminolysis. Biochem Pharmacol. 2022;198:114943.PubMedCrossRef
25.
26.
27.
28.
Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678–84.PubMedPubMedCentralCrossRef
29.
Bhutia YD, Babu E, Ramachandran S, Ganapathy V. Amino Acid transporters in cancer and their relevance to “glutamine addiction”: novel targets for the design of a new class of anticancer drugs. Cancer Res. 2015;75(9):1782–8.PubMedCrossRef
30.
Scalise M, Pappacoda G, Mazza T, Console L, Pochini L, Indiveri C. Cysteine 467 of the ASCT2 amino acid transporter is a molecular determinant of the antiport mechanism. Int J Mol Sci. 2022;23(3):1127.PubMedPubMedCentralCrossRef
31.
Sastrasinh M, Sastrasinh S. Effect of acute pH change on mitochondrial glutamine transport. Am J Physiol. 1990;259(6 Pt 2):F863–6.PubMed
32.
van Geldermalsen M, Wang Q, Nagarajah R, Marshall AD, Thoeng A, Gao D, et al. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2016;35(24):3201–8.PubMedCrossRef
33.
Toda K, Nishikawa G, Iwamoto M, Itatani Y, Takahashi R, Sakai Y, et al. Clinical role of ASCT2 (SLC1A5) in KRAS-mutated colorectal cancer. Int J Mol Sci. 2017;18(8):1632.PubMedPubMedCentralCrossRef
34.
Lin J, Yang T, Peng Z, Xiao H, Jiang N, Zhang L, et al. SLC1A5 silencing inhibits esophageal cancer growth via cell cycle arrest and apoptosis. Cell Physiol Biochem. 2018;48(1):397.PubMedCrossRef
35.
Wu J, Li Z, Yang Z, Guo L, Zhang Y, Deng H, et al. A Glutamine-rich carrier efficiently delivers anti-CD47 siRNA driven by a “Glutamine Trap” to inhibit lung cancer cell growth. Mol Pharm. 2018;15(8):3032–45.PubMedCrossRef
36.
Guo H, Xu Y, Wang F, Shen Z, Tuo X, Qian H, et al. Clinical associations between ASCT2 and p-mTOR in the pathogenesis and prognosis of epithelial ovarian cancer. Oncol Rep. 2018;40(6):3725–33.PubMed
37.
Wang Q, Hardie RA, Hoy AJ, van Geldermalsen M, Gao D, Fazli L, et al. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development. J Pathol. 2015;236(3):278–89.PubMedPubMedCentralCrossRef
38.
Liu Y, Yang L, An H, Chang Y, Zhang W, Zhu Y, et al. High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma. Sci Rep. 2015;5:16954.PubMedPubMedCentralCrossRef
39.
Zhang Z, Liu R, Shuai Y, Huang Y, Jin R, Wang X, et al. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma. Br J Cancer. 2020;122(1):82–93.PubMedCrossRef
40.
Jiang J, Dong W, Zhang W, Wang Q, Wang R, Wang J, et al. LncRNA SLC1A5-AS/MZF1/ASCT2 axis contributes to malignant progression of hepatocellular carcinoma. Discov Med. 2023;35(179):995–1014.PubMedCrossRef
41.
Fotiadis D, Kanai Y, Palacin M. The SLC3 and SLC7 families of amino acid transporters. Mol Aspects Med. 2013;34(2–3):139–58.PubMedCrossRef
42.
Fuchs BC, Bode BP. Amino acid transporters ASCT2 and LAT1 in cancer: partners in crime? Semin Cancer Biol. 2005;15(4):254–66.PubMedCrossRef
43.
Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521–34.PubMedPubMedCentralCrossRef
44.
Nachef M, Ali AK, Almutairi SM, Lee SH. Targeting SLC1A5 and SLC3A2/SLC7A5 as a potential strategy to strengthen anti-tumor immunity in the tumor microenvironment. Front Immunol. 2021;12:624324.PubMedPubMedCentralCrossRef
45.
Kurozumi S, Kaira K, Matsumoto H, Kurosumi M, Yokobori T, Kanai Y, et al. Association of L-type amino acid transporter 1 (LAT1) with the immune system and prognosis in invasive breast cancer. Sci Rep. 2022;12(1):2742.PubMedPubMedCentralCrossRef
46.
Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53(1):16–26.PubMedCrossRef
47.
Wang J, Chen X, Su L, Li P, Liu B, Zhu Z. LAT-1 functions as a promotor in gastric cancer associated with clinicopathologic features. Biomed Pharmacother. 2013;67(8):693–9.PubMedCrossRef
48.
Liu YH, Li YL, Shen HT, Chien PJ, Sheu GT, Wang BY, et al. L-type amino acid transporter 1 regulates cancer stemness and the expression of programmed cell death 1 ligand 1 in lung cancer cells. Int J Mol Sci. 2021;22(20):10955.PubMedPubMedCentralCrossRef
49.
Altan B, Kaira K, Watanabe A, Kubo N, Bao P, Dolgormaa G, et al. Relationship between LAT1 expression and resistance to chemotherapy in pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2018;81(1):141–53.PubMedCrossRef
50.
Xu M, Sakamoto S, Matsushima J, Kimura T, Ueda T, Mizokami A, et al. Up-regulation of LAT1 during antiandrogen therapy contributes to progression in prostate cancer cells. J Urol. 2016;195(5):1588–97.PubMedCrossRef
51.
Srisongkram T, Bahrami K, Jarvinen J, Timonen J, Rautio J, Weerapreeyakul N. Development of sesamol carbamate-L-phenylalanine prodrug targeting L-Type Amino Acid Transporter1 (LAT1) as a potential antiproliferative agent against melanoma. Int J Mol Sci. 2022;23(15):8446.PubMedPubMedCentralCrossRef
52.
Sato K, Miyamoto M, Takano M, Furuya K, Tsuda H. Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. Virchows Arch. 2019;474(6):701–10.PubMedCrossRef
53.
Namikawa M, Kakizaki S, Kaira K, Tojima H, Yamazaki Y, Horiguchi N, et al. Expression of amino acid transporters (LAT1, ASCT2 and xCT) as clinical significance in hepatocellular carcinoma. Hepatol Res. 2015;45(9):1014–22.PubMedCrossRef
54.
Chen Z, Gao Y, Huang X, Yao Y, Chen K, Zeng S, et al. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma. J Pharm Biomed Anal. 2021;197:113937.PubMedCrossRef
55.
Sniegowski T, Korac K, Bhutia YD, Ganapathy V. SLC6A14 and SLC38A5 drive the glutaminolysis and serine-glycine-one-carbon pathways in cancer. Pharmaceuticals (Basel). 2021;14(3):216.PubMedPubMedCentralCrossRef
56.
Sloan JL, Mager S. Cloning and functional expression of a human Na(+) and Cl(-)-dependent neutral and cationic amino acid transporter B(0+). J Biol Chem. 1999;274(34):23740–5.PubMedCrossRef
57.
Gupta N, Prasad PD, Ghamande S, Moore-Martin P, Herdman AV, Martindale RG, et al. Up-regulation of the amino acid transporter ATB(0,+) (SLC6A14) in carcinoma of the cervix. Gynecol Oncol. 2006;100(1):8–13.PubMedCrossRef
58.
Karunakaran S, Ramachandran S, Coothankandaswamy V, Elangovan S, Babu E, Periyasamy-Thandavan S, et al. SLC6A14 (ATB0,+) protein, a highly concentrative and broad specific amino acid transporter, is a novel and effective drug target for treatment of estrogen receptor-positive breast cancer. J Biol Chem. 2011;286(36):31830–8.PubMedPubMedCentralCrossRef
59.
Coothankandaswamy V, Cao S, Xu Y, Prasad PD, Singh PK, Reynolds CP, et al. Amino acid transporter SLC6A14 is a novel and effective drug target for pancreatic cancer. Br J Pharmacol. 2016;173(23):3292–306.PubMedPubMedCentralCrossRef
60.
Guo Q, Xu W, Li X, Sun JL, Gu XC, Jing FB. SLC6A14 depletion contributes to amino acid starvation to suppress EMT-induced metastasis in gastric cancer by perturbing the PI3K/AKT/mTORC1 pathway. Biomed Res Int. 2022;2022:7850658.PubMedPubMedCentralCrossRef
61.
Taurino G, Chiu M, Bianchi MG, Griffini E, Bussolati O. The SLC38A5/SNAT5 amino acid transporter: from pathophysiology to pro-cancer roles in the tumor microenvironment. Am J Physiol Cell Physiol. 2023;325(2):C550–62.PubMedCrossRef
62.
Wang K, Cao F, Fang W, Hu Y, Chen Y, Ding H, et al. Activation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression. BMC Cancer. 2013;13:343.PubMedPubMedCentralCrossRef
63.
Xie J, Li P, Gao HF, Qian JX, Yuan LY, Wang JJ. Overexpression of SLC38A1 is associated with poorer prognosis in Chinese patients with gastric cancer. BMC Gastroenterol. 2014;14:70.PubMedPubMedCentralCrossRef
64.
Zhou FF, Xie W, Chen SQ, Wang XK, Liu Q, Pan XK, et al. SLC38A1 promotes proliferation and migration of human colorectal cancer cells. J Huazhong Univ Sci Technolog Med Sci. 2017;37(1):30–6.PubMedCrossRef
65.
Liu L, Su S, Ye D, Yu Z, Lu W, Li X. Long non-coding RNA OGFRP1 regulates cell proliferation and ferroptosis by miR-299-3p/SLC38A1 axis in lung cancer. Anticancer Drugs. 2022;33(9):826–39.PubMedCrossRef
66.
Liu Y, Yang Y, Jiang L, Xu H, Wei J. High expression levels of SLC38A1 are correlated with poor prognosis and defective immune infiltration in hepatocellular carcinoma. J Oncol. 2021;2021:5680968.PubMedPubMedCentralCrossRef
67.
68.
Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport mechanism and intracellular fate of trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med. 2011;52(5):822–9.PubMedCrossRef
69.
Sudo H, Tsuji AB, Sugyo A, Okada M, Kato K, Zhang MR, et al. Direct comparison of 2-amino[3-11C] isobutyric acid and 2-amino[11C]methyl-isobutyric acid uptake in eight lung cancer xenograft models. Int J Oncol. 2018;53(6):2737–44.PubMed
70.
Zhao X, Jin L, Liu Y, Liu Z, Liu Q. Bioinformatic analysis of the role of solute carrier-glutamine transporters in breast cancer. Ann Transl Med. 2022;10(14):777.PubMedPubMedCentralCrossRef
71.
Morotti M, Zois CE, El-Ansari R, Craze ML, Rakha EA, Fan SJ, et al. Increased expression of glutamine transporter SNAT2/SLC38A2 promotes glutamine dependence and oxidative stress resistance, and is associated with worse prognosis in triple-negative breast cancer. Br J Cancer. 2021;124(2):494–505.PubMedCrossRef
72.
Morotti M, Bridges E, Valli A, Choudhry H, Sheldon H, Wigfield S, et al. Hypoxia-induced switch in SNAT2/SLC38A2 regulation generates endocrine resistance in breast cancer. Proc Natl Acad Sci U S A. 2019;116(25):12452–61.PubMedPubMedCentralCrossRef
73.
Wang Y, Fu L, Cui M, Wang Y, Xu Y, Li M, et al. Amino acid transporter SLC38A3 promotes metastasis of non-small cell lung cancer cells by activating PDK1. Cancer Lett. 2017;393:8–15.PubMedCrossRef
74.
Ramachandran S, S RS, Sharma M, Thangaraju M, V VS, Sneigowski T, et al. Expression and function of SLC38A5, an amino acid-coupled Na+/H+ exchanger, in triple-negative breast cancer and its relevance to macropinocytosis. Biochem J. 2021;478(21):3957–76.CrossRef
75.
Kim MJ, Kim HS, Kang HW, Lee DE, Hong WC, Kim JH, et al. SLC38A5 modulates ferroptosis to overcome gemcitabine resistance in pancreatic cancer. Cells-Basel. 2023;12(20):2509.CrossRef
76.
Shen X, Wang G, He H, Shang P, Yan B, Wang X, et al. SLC38A5 promotes glutamine metabolism and inhibits cisplatin chemosensitivity in breast cancer. Breast Cancer. 2024;31(1):96–104.PubMedCrossRef
77.
Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–94.PubMedCrossRef
78.
Sellers K, Fox MP, Bousamra M 2nd, Slone SP, Higashi RM, Miller DM, et al. Pyruvate carboxylase is critical for non-small-cell lung cancer proliferation. J Clin Invest. 2015;125(2):687–98.PubMedPubMedCentralCrossRef
79.
Gaglio D, Soldati C, Vanoni M, Alberghina L, Chiaradonna F. Glutamine deprivation induces abortive s-phase rescued by deoxyribonucleotides in k-ras transformed fibroblasts. PLoS One. 2009;4(3):e4715.PubMedPubMedCentralCrossRef
80.
Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, Coller HA, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010;17(3):225–34.PubMedPubMedCentralCrossRef
81.
Welbourne TC. Ammonia production and glutamine incorporation into glutathione in the functioning rat kidney. Can J Biochem. 1979;57(3):233–7.PubMedCrossRef
82.
Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45(10):1134–40.PubMedPubMedCentralCrossRef
83.
Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol. 2007;178(1):93–105.PubMedPubMedCentralCrossRef
84.
Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458(7239):762–5.PubMedPubMedCentralCrossRef
85.
Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105(48):18782–7.PubMedPubMedCentralCrossRef
86.
Anso E, Mullen AR, Felsher DW, Mates JM, Deberardinis RJ, Chandel NS. Metabolic changes in cancer cells upon suppression of MYC. Cancer Metab. 2013;1(1):7.PubMedPubMedCentralCrossRef
87.
Jeong SM, Lee A, Lee J, Haigis MC. SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma. J Biol Chem. 2014;289(7):4135–44.PubMedCrossRef
88.
Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. Proc Natl Acad Sci U S A. 2015;112(21):6539–44.PubMedPubMedCentralCrossRef
89.
Dejure FR, Royla N, Herold S, Kalb J, Walz S, Ade CP, et al. The MYC mRNA 3’-UTR couples RNA polymerase II function to glutamine and ribonucleotide levels. EMBO J. 2017;36(13):1854–68.PubMedPubMedCentralCrossRef
90.
Munksgaard Thoren M, Vaapil M, Staaf J, Planck M, Johansson ME, Mohlin S, et al. Myc-induced glutaminolysis bypasses HIF-driven glycolysis in hypoxic small cell lung carcinoma cells. Oncotarget. 2017;8(30):48983–95.PubMedCrossRef
91.
Kandasamy P, Zlobec I, Nydegger DT, Pujol-Gimenez J, Bhardwaj R, Shirasawa S, et al. Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1. Mol Oncol. 2021;15(10):2782–800.PubMedPubMedCentralCrossRef
92.
Zhu Q, Zhou H, Wu L, Lai Z, Geng D, Yang W, et al. O-GlcNAcylation promotes pancreatic tumor growth by regulating malate dehydrogenase 1. Nat Chem Biol. 2022;18(10):1087–95.PubMedCrossRef
93.
Meijer TWH, Looijen-Salamon MG, Lok J, van den Heuvel M, Tops B, Kaanders J, et al. Glucose and glutamine metabolism in relation to mutational status in NSCLC histological subtypes. Thorac Cancer. 2019;10(12):2289–99.PubMedPubMedCentralCrossRef
94.
95.
Grzmil M, Wiesmann F, Schibli R, Behe M. Targeting mTORC1 activity to improve efficacy of radioligand therapy in cancer. Cancers (Basel). 2022;15(1):17.PubMedPubMedCentralCrossRef
96.
Ni R, Li Z, Li L, Peng D, Ming Y, Li L, et al. Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer. Front Oncol. 2023;13:1143798.PubMedPubMedCentralCrossRef
97.
Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, Yoon SO, et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell. 2010;38(4):487–99.PubMedPubMedCentralCrossRef
98.
Csibi A, Fendt SM, Li C, Poulogiannis G, Choo AY, Chapski DJ, et al. The mTORC1 pathway stimulates glutamine metabolism and cell proliferation by repressing SIRT4. Cell. 2013;153(4):840–54.PubMedPubMedCentralCrossRef
99.
Csibi A, Lee G, Yoon SO, Tong H, Ilter D, Elia I, et al. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eIF4B-dependent control of c-Myc translation. Curr Biol. 2014;24(19):2274–80.PubMedPubMedCentralCrossRef
100.
Chen M, Wang G, Xu Z, Sun J, Liu B, Chang L, et al. Loss of RACK1 promotes glutamine addiction via activating AKT/mTOR/ASCT2 axis to facilitate tumor growth in gastric cancer. Cell Oncol (Dordr). 2024;47(1):113–28.
101.
Hao Y, Samuels Y, Li Q, Krokowski D, Guan BJ, Wang C, et al. Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer. Nat Commun. 2016;7:11971.PubMedPubMedCentralCrossRef
102.
Oh DY, Bang YJ. HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17(1):33–48.PubMedCrossRef
103.
Qie S, Chu C, Li W, Wang C, Sang N. ErbB2 activation upregulates glutaminase 1 expression which promotes breast cancer cell proliferation. J Cell Biochem. 2014;115(3):498–509.PubMedPubMedCentralCrossRef
104.
Hu X, Ma Z, Xu B, Li S, Yao Z, Liang B, et al. Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2-positive gastric cancer. Cancer Commun (Lond). 2023;43(8):909–37.PubMedCrossRef
105.
Xiao-Yan W, Xiao-Xia Y, Peng-Fei S, Zong-Xue Z, Xiu-Li G. Metabolic reprogramming of glutamine involved in tumorigenesis, multidrug resistance and tumor immunity. Eur J Pharmacol. 2023;940:175323.PubMedCrossRef
106.
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A. 2010;107(16):7461–6.PubMedPubMedCentralCrossRef
107.
108.
Lukey MJ, Greene KS, Erickson JW, Wilson KF, Cerione RA. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun. 2016;7:11321.PubMedPubMedCentralCrossRef
109.
Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, et al. Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol. 2016;10(1):73–84.PubMedCrossRef
110.
Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell. 2012;149(1):49–62.PubMedPubMedCentralCrossRef
111.
Reynolds MR, Lane AN, Robertson B, Kemp S, Liu Y, Hill BG, et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene. 2014;33(5):556–66.PubMedCrossRef
112.
Lee SY, Jeon HM, Ju MK, Jeong EK, Kim CH, Park HG, et al. Dlx-2 and glutaminase upregulate epithelial-mesenchymal transition and glycolytic switch. Oncotarget. 2016;7(7):7925–39.PubMedPubMedCentralCrossRef
113.
Newsholme P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr. 2001;131(9):2515S–22S.
114.
Cruzat V, MacedoRogero M, Noel Keane K, Curi R, Newsholme P. Glutamine: metabolism and immune function, supplementation and clinical translation. Nutrients. 2018;10(11):1564.PubMedPubMedCentralCrossRef
115.
Mills EL, Kelly B, O’Neill LAJ. Mitochondria are the powerhouses of immunity. Nat Immunol. 2017;18(5):488–98.PubMedCrossRef
116.
Ardawi MS, Newsholme EA. Intracellular localization and properties of phosphate-dependent glutaminase in rat mesenteric lymph nodes. Biochem J. 1984;217(1):289–96.PubMedPubMedCentralCrossRef
117.
Jensen H, Potempa M, Gotthardt D, Lanier LL. Cutting edge: IL-2-induced expression of the amino acid transporters SLC1A5 and CD98 is a prerequisite for NKG2D-mediated activation of human NK cells. J Immunol. 2017;199(6):1967–72.PubMedCrossRef
118.
Maciolek JA, Pasternak JA, Wilson HL. Metabolism of activated T lymphocytes. Curr Opin Immunol. 2014;27:60–74.PubMedCrossRef
119.
Nakaya M, Xiao Y, Zhou X, Chang JH, Chang M, Cheng X, et al. Inflammatory T cell responses rely on amino acid transporter ASCT2 facilitation of glutamine uptake and mTORC1 kinase activation. Immunity. 2014;40(5):692–705.PubMedPubMedCentralCrossRef
120.
Huang H, Zhou P, Wei J, Long L, Shi H, Dhungana Y, et al. In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8(+) T cell fate decisions. Cell. 2021;184(5):1245–61 e21.PubMedPubMedCentralCrossRef
121.
Jiang S, Yan W, Wang SE, Baltimore D. Let-7 suppresses B cell activation through restricting the availability of necessary nutrients. Cell Metab. 2018;27(2):393.PubMedCrossRef
122.
Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;10:889–96.CrossRef
123.
Liu PS, Wang H, Li X, Chao T, Teav T, Christen S, et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol. 2017.
124.
Newsholme Philip. Why is l-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr. 2001.
125.
Ren W, Xia Y, Chen S, Wu G, Bazer FW, Zhou B, et al. Glutamine metabolism in macrophages: a novel target for obesity/type 2 diabetes. Adv Nutr. 2019;10(2):321–30.PubMedPubMedCentralCrossRef
126.
Liu PS, Chen YT, Li X, Hsueh PC, Tzeng SF, Chen H, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol. 2023;24(3):452–62.PubMedPubMedCentralCrossRef
127.
Loftus RM, Assmann N, Kedia-Mehta N, O’Brien KL, Garcia A, Gillespie C, et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun. 2018;9(1):2341.PubMedPubMedCentralCrossRef
128.
Presnell SR, Spear HK, Durham J, Riddle T, Applegate A, Lutz CT. Differential fuel requirements of human NK cells and human CD8 T cells: glutamine regulates glucose uptake in strongly activated CD8 T cells. Immunohorizons. 2020;4(5):231–44.PubMedCrossRef
129.
Ricciardi S, Manfrini N, Alfieri R, Calamita P, Crosti MC, Gallo S, et al. The translational machinery of human CD4(+) T cells is poised for activation and controls the switch from quiescence to metabolic remodeling. Cell Metab. 2018;28(6):895–906 e5.PubMedPubMedCentralCrossRef
130.
Sinclair LV, Rolf J, Emslie E, Shi Y-B, Taylor PM, Cantrell DA. Control of amino-acid transport by antigen receptors coordinates the metabolic reprogramming essential for T cell differentiation. Nat Immunol. 2013;14(5):500–8.PubMedPubMedCentralCrossRef
131.
Carr EL, Kelman A, Wu GS, Gopaul R, Senkevitch E, Aghvanyan A, et al. Glutamine uptake and metabolism are coordinately regulated by ERK/MAPK during T lymphocyte activation. J Immunol. 2010;185(2):1037–44.PubMedCrossRef
132.
Lee K, Thompson EA, Gharaie S, Patel CH, Kurzhagen JT, Pierorazio PM, et al. T cell metabolic reprogramming in acute kidney injury and protection by glutamine blockade. JCI Insight. 2023;8(12):e160345.PubMedPubMedCentralCrossRef
133.
Madi A, Weisshaar N, Buettner M, Poschet G, Ma S, Wu J, et al. CD8 agonism functionally activates memory T cells and enhances antitumor immunity. Int J Cancer. 2022;151(5):797–808.PubMedCrossRef
134.
Edwards DN, Ngwa VM, Raybuck AL, Wang S, Hwang Y, Kim LC, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131(4):e140100.PubMedPubMedCentralCrossRef
135.
Sakai C, Nishikawa H. Immunosuppressive environment in tumors. Gan To Kagaku Ryoho. 2018;45(2):222–6.PubMed
136.
Yang G, Xia Y, Ren W. Glutamine metabolism in Th17/Treg cell fate: applications in Th17 cell-associated diseases. Sci China Life Sci. 2021;64(2):221–33.PubMedCrossRef
137.
Kumar A, Yarosz EL, Andren A, Zhang L, Lyssiotis CA, Chang CH. NKT cells adopt a glutamine-addicted phenotype to regulate their homeostasis and function. Cell Rep. 2022;41(4):111516.PubMedPubMedCentralCrossRef
138.
Crawford J, Cohen HJ. The essential role of L-glutamine in lymphocyte differentiation in vitro. J Cell Physiol. 1985;124(2):275–82.PubMedCrossRef
139.
Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab. 2012;15(1):110–21.PubMedPubMedCentralCrossRef
140.
Waters LR, Ahsan FM, Wolf DM, Shirihai O, Teitell MA. Initial B cell activation induces metabolic reprogramming and mitochondrial remodeling. iScience. 2018;5:99–109.PubMedPubMedCentralCrossRef
141.
Zhang X, Wang G, Bi Y, Jiang Z, Wang X. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1beta pathways in MRL/lpr mice. Int Immunopharmacol. 2022;112:109133.PubMedCrossRef
142.
Mielle J, Morel J, Elhmioui J, Combe B, Macia L, Dardalhon V, et al. Glutamine promotes the generation of B10(+) cells via the mTOR/GSK3 pathway. Eur J Immunol. 2022;52(3):418–30.PubMedCrossRef
143.
Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11(8):519–31.PubMedCrossRef
144.
Pithon-Curi TC, De Melo MP, Curi R. Glucose and glutamine utilization by rat lymphocytes, monocytes and neutrophils in culture: a comparative study. Cell Biochem Funct. 2004;22(5):321–6.PubMedCrossRef
145.
Pithon-Curi TC, Trezena AG, Tavares-Lima W, Curi R. Evidence that glutamine is involved in neutrophil function. Cell Biochem Funct. 2002;20(2):81–6.PubMedCrossRef
146.
Lagranha CJ, Senna SM, de Lima TM, Silva E, Doi SQ, Curi R, et al. Beneficial effect of glutamine on exercise-induced apoptosis of rat neutrophils. Med Sci Sports Exerc. 2004;36(2):210–7.PubMedCrossRef
147.
Oh MH, Sun IH, Zhao L, Leone RD, Sun IM, Xu W, et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J Clin Investig. 2020;130(7):3865–84.PubMedPubMedCentralCrossRef
148.
Kao KC, Vilbois S, Tsai CH, Ho PC. Metabolic communication in the tumour-immune microenvironment. Nat Cell Biol. 2022;24(11):1574–83.PubMedCrossRef
149.
Wilmore DW, Shabert JK. Role of glutamine in immunologic responses. Nutrition. 1998;7/8:14.
150.
151.
Chen JF, Wang R, Liu ZL, Fan J, Liu SL, Tan SD, et al. Unbalanced glutamine partitioning between CD8T cells and cancer cells accompanied by immune cell dysfunction in hepatocellular carcinoma. Cells-Basel. 2022;11(23):3924.CrossRef
152.
Chang CH, Qiu J, O’Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229–41.PubMedPubMedCentralCrossRef
153.
Chen P, Han Y, Wang L, Zheng Y, Zhu Z, Zhao Y, et al. Spatially resolved metabolomics combined with the 3d tumor-immune cell coculture spheroid highlights metabolic alterations during antitumor immune response. Anal Chem. 2023;95(41):15153–61.PubMedCrossRef
154.
Zhang X, Halberstam AA, Zhu W, Leitner BP, Thakral D, Bosenberg MW, et al. Isotope tracing reveals distinct substrate preference in murine melanoma subtypes with differing anti-tumor immunity. Cancer Metab. 2022;10(1):21.PubMedPubMedCentralCrossRef
155.
Kondo M, Kumagai S, Nishikawa H. Metabolic advantages of regulatory T cells dictated by cancer cells. Int Immunol. 2024;36(2):75–86.
156.
Tsai CC, Tiao MM, Sheen JM, Huang LT, Tain YL, Lin IC, et al. Obesity programmed by prenatal dexamethasone and postnatal high-fat diet leads to distinct alterations in nutrition sensory signals and circadian-clock genes in visceral adipose tissue. Lipids Health Dis. 2019;18(1):19.PubMedPubMedCentralCrossRef
157.
Battu S, Minhas G, Mishra A, Khan N. Amino acid sensing via general control nonderepressible-2 kinase and immunological programming. Front Immunol. 2017;8:1719.PubMedPubMedCentralCrossRef
158.
Willinger T, Staron M, Ferguson SM, De Camilli P, Flavell RA. Dynamin 2-dependent endocytosis sustains T-cell receptor signaling and drives metabolic reprogramming in T lymphocytes. Proc Natl Acad Sci U S A. 2015;112(14):4423–8.PubMedPubMedCentralCrossRef
159.
Shi H, Chapman NM, Wen J, Guy C, Long L, Dhungana Y, et al. Amino acids license kinase mTORC1 activity and treg cell function via small G proteins rag and rheb. Immunity. 2019;51(6):1012–27 e7.PubMedPubMedCentralCrossRef
160.
Metzler B, Gfeller P, Guinet E. Restricting glutamine or glutamine-dependent purine and pyrimidine syntheses promotes human T cells with high FOXP3 expression and regulatory properties. J Immunol. 2016;196(9):3618–30.PubMedCrossRef
161.
Liu JQ, Geng XR, Hu TY, Mo LH, Luo XQ, Qiu SY, et al. Glutaminolysis is required in maintaining immune regulatory functions in B cells. Mucosal Immunol. 2022;15(2):268–78.PubMedCrossRef
162.
Loftus RM, Assmann N, Kedia-Mehta N, O’Brien KL, Garcia A, Gillespie C, et al. Amino acid-dependent cMyc expression is essential for NK cell metabolic and functional responses in mice. Nat Commun. 2018;9(1):2341.PubMedPubMedCentralCrossRef
163.
Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–68.PubMedPubMedCentralCrossRef
164.
Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017;14(4):203–20.PubMedCrossRef
165.
Zheng Y, Yao Y, Ge T, Ge S, Jia R, Song X, et al. Amino acid metabolism reprogramming: shedding new light on T cell anti-tumor immunity. J Exp Clin Cancer Res. 2023;42(1):291.PubMedPubMedCentralCrossRef
166.
Byun JK, Park M, Lee S, Yun JW, Lee J, Kim JS, et al. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell. 2020;80(4):592–606 e8.PubMedCrossRef
167.
168.
Ma G, Liang Y, Chen Y, Wang L, Li D, Liang Z, et al. Glutamine deprivation induces PD-L1 expression via activation of EGFR/ERK/c-jun signaling in renal cancer. Mol Cancer Res. 2020;18(2):324–39.PubMedCrossRef
169.
Wang L, Xu T, Yang X, Liang Z, Zhang J, Li D, et al. Immunosuppression induced by glutamine deprivation occurs via activating PD-L1 transcription in bladder cancer. Front Mol Biosci. 2021;8:687305.PubMedPubMedCentralCrossRef
170.
Byun JK, Park M, Lee S, Yun JW, Lee J, Kim JS, et al. Inhibition of glutamine utilization synergizes with immune checkpoint inhibitor to promote antitumor immunity. Mol Cell. 2020;80(4):592-+.PubMedCrossRef
171.
Zhao L, Rao X, Zheng R, Huang C, Kong R, Yu X, et al. Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. J Control Release. 2023;357:460–71.PubMedCrossRef
172.
Gao Y, Zhang H, Tang L, Li F, Yang L, Xiao H, et al. Cancer Nanobombs Delivering Artoxplatin with a Polyigniter Bearing Hydrophobic Ferrocene Units Upregulate PD-L1 Expression and Stimulate Stronger Anticancer Immunity. Adv Sci (Weinh). 2024;11(4):e2300806.
173.
Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, et al. Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma. Can Res. 2007;67(5):2298–305.CrossRef
174.
Best SA, Gubser PM, Sethumadhavan S, Kersbergen A, Abril YLN, Goldford J, et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab. 2022;34(6):874-+.PubMedCrossRef
175.
Xiong TT, He P, Zhou M, Zhong D, Yang T, He WH, et al. Glutamate blunts cell-killing effects of neutrophils in tumor microenvironment. Cancer Sci. 2022;113(6):1955–67.PubMedPubMedCentralCrossRef
176.
Robert SM, Sontheimer H. Glutamate transporters in the biology of malignant gliomas. Cell Mol Life Sci. 2014;71(10):1839–54.PubMedCrossRef
177.
Morikawa N, Tachibana M, Ago Y, Goda H, Sakurai F, Mizuguchi H. LY341495, an mGluR2/3 antagonist, regulates the immunosuppressive function of myeloid-derived suppressor cells and inhibits melanoma tumor growth. Biol Pharm Bull. 2018;41(12):1866–9.PubMedCrossRef
178.
Pacheco R, Ciruela F, Casadó V, Mallol J, Gallart T, Lluis C, et al. Group I metabotropic glutamate receptors mediate a dual role of glutamate in T cell activation. J Biol Chem. 2004;279(32):33352–8.PubMedCrossRef
179.
Siska PJ, Kim B, Ji XM, Hoeksema MD, Massion PP, Beckermann KE, et al. Fluorescence-based measurement of cystine uptake through xCT shows requirement for ROS detoxification in activated lymphocytes. J Immunol Methods. 2016;438:51–8.PubMedPubMedCentralCrossRef
180.
Koda S, Hu J, Ju XM, Sun GW, Shao SM, Tang RX, et al. The role of glutamate receptors in the regulation of the tumor microenvironment. Front Immunol. 2023;14:1123841.PubMedPubMedCentralCrossRef
181.
Lukey MJ, Wilson KF, Cerione RA. Therapeutic strategies impacting cancer cell glutamine metabolism. Future Med Chem. 2013;5(14):1685–700.PubMedCrossRef
182.
Magill GB, Myers WP, Reilly HC, Putnam RC, Magill JW, Sykes MP, et al. Pharmacological and initial therapeutic observations on 6-diazo-5-oxo-1-norleucine (DON) in human neoplastic disease. Cancer. 1957;10(6):1138–50.PubMedCrossRef
183.
Sharma NS, Gupta VK, Garrido VT, Hadad R, Durden BC, Kesh K, et al. Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy. J Clin Invest. 2020;130(1):451–65.PubMedCrossRef
184.
Frejlachova A, Lencova R, Venhauerova A, Skalickova M, Uher O, Caisova V, et al. The combination of immunotherapy and a glutamine metabolism inhibitor represents an effective therapeutic strategy for advanced and metastatic murine pancreatic adenocarcinoma. Int Immunopharmacol. 2023;118:110150.PubMedCrossRef
185.
Huang M, Xiong D, Pan J, Zhang Q, Sei S, Shoemaker RH, et al. Targeting glutamine metabolism to enhance immunoprevention of EGFR-driven lung cancer. Adv Sci (Weinh). 2022;9(26):e2105885.PubMedCrossRef
186.
Yokoyama Y, Estok TM, Wild R. Sirpiglenastat (DRP-104) induces antitumor efficacy through direct, broad antagonism of glutamine metabolism and stimulation of the innate and adaptive immune systems. Mol Cancer Ther. 2022;21(10):1561–72.PubMedCrossRef
187.
Rais R, Lemberg KM, Tenora L, Arwood ML, Pal A, Alt J, et al. Discovery of DRP-104, a tumor-targeted metabolic inhibitor prodrug. Sci Adv. 2022;8(46):eabq5925.PubMedPubMedCentralCrossRef
188.
Pillai R, LeBoeuf SE, Hao Y, New C, Blum JLE, Rashidfarrokhi A, et al. Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in KEAP1 mutant lung cancer. bioRxiv. 2023.
189.
Jin L, Alesi GN, Kang S. Glutaminolysis as a target for cancer therapy. Oncogene. 2016;35(28):3619–25.PubMedCrossRef
190.
Kanai Y, Hediger MA. The glutamate/neutral amino acid transporter family SLC1: molecular, physiological and pharmacological aspects. Pflugers Arch. 2004;447(5):469–79.PubMedCrossRef
191.
Schulte ML, Fu A, Zhao P, Li J, Geng L, Smith ST, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models. Nat Med. 2018;24(2):194–202.PubMedPubMedCentralCrossRef
192.
Han L, Zhou J, Li L, Wu X, Shi Y, Cui W, et al. SLC1A5 enhances malignant phenotypes through modulating ferroptosis status and immune microenvironment in glioma. Cell Death Dis. 2022;13(12):1071.PubMedPubMedCentralCrossRef
193.
Li Q, Zhong X, Yao W, Yu J, Wang C, Li Z, et al. Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. J Biol Chem. 2022;298(4):101753.PubMedPubMedCentralCrossRef
194.
Tang Y, Wang S, Li Y, Yuan C, Zhang J, Xu Z, et al. Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer. J Nanobiotechnol. 2022;20(1):216.CrossRef
195.
Scalise M, Pochini L, Galluccio M, Console L, Indiveri C. Glutamine transport and mitochondrial metabolism in cancer cell growth. Front Oncol. 2017;7:306.PubMedPubMedCentralCrossRef
196.
Huang R, Wang H, Hong J, Wu J, Huang O, He J, et al. Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. Front Immunol. 2023;14:1251643.PubMedPubMedCentralCrossRef
197.
198.
Meléndez-Rodríguez F, Urrutia AA, Lorendeau D, Rinaldi G, Roche O, Böğürcü-Seidel N, et al. HIF1a suppresses tumor cell proliferation through inhibition of aspartate biosynthesis. Cell Rep. 2019;26(9):2257–65.e4.PubMedCrossRef
199.
Varghese S, Pramanik S, Williams LJ, Hodges HR, Hudgens CW, Fischer GM, et al. The glutaminase inhibitor CB-839 (Telaglenastat) enhances the antimelanoma activity of t-cell-mediated immunotherapies. Mol Cancer Ther. 2021;20(3):500–11.PubMedCrossRef
200.
Best SA, Gubser PM, Sethumadhavan S, Kersbergen A, Negron Abril YL, Goldford J, et al. Glutaminase inhibition impairs CD8 T cell activation in STK11-/Lkb1-deficient lung cancer. Cell Metab. 2022;34(6):874–87 e6.PubMedCrossRef
201.
Zhang R, Li R, Zhang L, Chen G, Mo L, Jiang R, et al. A dual-mechanism based nutrient partitioning nanoregulator for enhanced immunotherapy against anti-PD-1 resistant tumors. ACS Nano. 2023;17(14):13461–73.PubMedCrossRef
202.
Wang JJ, Siu MK, Jiang YX, Leung TH, Chan DW, Wang HG, et al. A combination of glutaminase inhibitor 968 and PD-L1 blockade boosts the immune response against ovarian cancer. Biomolecules. 2021;11(12):1749.PubMedPubMedCentralCrossRef
203.
Mai Z, Zhong J, Zhang J, Chen G, Tang Y, Ma W, et al. Carrier-free immunotherapeutic nano-booster with dual synergistic effects based on glutaminase inhibition combined with photodynamic therapy. ACS Nano. 2023;17(2):1583–96.
204.
Jin XK, Zhang SM, Liang JL, Zhang SK, Qin YT, Huang QX, et al. A PD-L1-targeting regulator for metabolic reprogramming to enhance glutamine inhibition-mediated synergistic antitumor metabolic and immune therapy. Adv Mater. 2023:36(6):e2309094.
205.
Zhang J, Wei L, Ma X, Wang J, Liang S, Chen K, et al. pH-sensitive tumor-tropism hybrid membrane-coated nanoparticles for reprogramming the tumor microenvironment and boosting the antitumor immunity. Acta Biomater. 2023;166:470–84.PubMedCrossRef
206.
Ren J, Zhou J, Liu H, Jiao X, Cao Y, Xu Z, et al. Ultrasound (US)-activated redox dyshomeostasis therapy reinforced by immunogenic cell death (ICD) through a mitochondrial targeting liposomal nanosystem. Theranostics. 2021;11(19):9470–91.PubMedPubMedCentralCrossRef
207.
Kang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, et al. EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer. Cell Rep. 2022;41(11):111827.PubMedPubMedCentralCrossRef
208.
Abrego J, Sanford-Crane H, Oon C, Xiao X, Betts CB, Sun D, et al. A cancer cell-intrinsic GOT2-PPARdelta axis suppresses antitumor immunity. Cancer Discov. 2022;12(10):2414–33.PubMedPubMedCentralCrossRef
209.
Wang B, Pei J, Xu S, Liu J, Yu J. System analysis based on glutamine catabolic-related enzymes identifies GPT2 as a novel immunotherapy target for lung adenocarcinoma. Comput Biol Med. 2023;165:107415.PubMedCrossRef
210.
Kim M, Gwak J, Hwang S, Yang S, Jeong SM. Mitochondrial GPT2 plays a pivotal role in metabolic adaptation to the perturbation of mitochondrial glutamine metabolism. Oncogene. 2019;38(24):4729–38.PubMedCrossRef
211.
Yang Y, He P, Hou Y, Liu Z, Zhang X, Li N. Osmundacetone modulates mitochondrial metabolism in non-small cell lung cancer cells by hijacking the glutamine/glutamate/alpha-KG metabolic axis. Phytomedicine. 2022;100:154075.PubMedCrossRef
212.
Wang ES, Frankfurt O, Orford KW, Bennett M, Konopleva M. Phase 1 study of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase in patients with relapsed/refractory leukemia. Blood. 2015;126(23):2566.CrossRef
213.
Vogl DT, Younes A, Stewart K, Orford KW, Berdeja JG. Phase 1 study of CB-839, a first-in-class, glutaminase inhibitor in patients with multiple myeloma and lymphoma. Blood. 2015;126(23):3059.CrossRef
214.
Harding JJ, Telli ML, Munster PN, Le MH, Molineaux C, Bennett MK, et al. Safety and tolerability of increasing doses of CB-839, a first-in-class, orally administered small molecule inhibitor of glutaminase, in solid tumors. J Clin Oncol. 2015;33(15):2512.
215.
DeMichele A, Harding JJ, Telli ML, Munster PN, Mckay R, Iliopoulos O, et al. Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC). J Clin Oncol. 2016;34(15):1011.
216.
Meric-Bernstam F, Lee RJ, Carthon BC, Iliopoulos O, Mier JW, Patel MR, et al. CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): results of a phase i study. J Clin Oncol. 2019;37(7):549.
217.
Meric-Bernstam F, Tannir N, Harding J, Voss M, Mier J, DeMichele A, et al. 26 - Phase 1 study of CB-839, a small molecule inhibitor of glutaminase, in combination with everolimus in patients (pts) with clear cell and papillary renal cell cancer (RCC). Eur J Cancer. 2016;69:S12–3.CrossRef
218.
Tannir NM, Agarwal N, Dawson NA, Motzer RJ, Jacobs CM, Choueiri TK, et al. CANTATA: Randomized, international, double-blind study of CB-839 plus cabozantinib versus cabozantinib plus placebo in patients with metastatic renal cell carcinoma. J Clin Oncol. 2019;37(7):TPS682.
219.
Wang D, Li X, Gong G, Lu Y, Guo Z, Chen R, et al. An updated patent review of glutaminase inhibitors (2019–2022). Expert Opin Ther Pat. 2023;33(1):17–28.PubMedCrossRef
220.
Soth MJ, Le K, Di Francesco ME, Hamilton MM, Liu G, Burke JP, et al. Discovery of IPN60090, a clinical stage selective glutaminase-1 (GLS-1) inhibitor with excellent pharmacokinetic and physicochemical properties. J Med Chem. 2020;63(21):12957–77.PubMedPubMedCentralCrossRef
221.
Fu Y, Liu S, Zeng S, Shen H. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38(1):396.PubMedPubMedCentralCrossRef
222.
Jing X, Yang F, Shao C, Wei K, Xie M, Shen H, et al. Role of hypoxia in cancer therapy by regulating the tumor microenvironment. Mol Cancer. 2019;18(1):157.PubMedPubMedCentralCrossRef
223.
224.
Madden MZ, Ye X, Chi C, Fisher EL, Wolf MM, Needle GA, et al. Differential effects of glutamine inhibition strategies on antitumor CD8 T cells. J Immunol. 2023;211(4):563–75.PubMedCrossRef
225.
Ahluwalia GS, Grem JL, Hao Z, Cooney DA. Metabolism and action of amino acid analog anti-cancer agents. Pharmacol Ther. 1990;46(2):243–71.PubMedCrossRef
Metadata
Title
A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle
Authors
Bolin Wang
Jinli Pei
Shengnan Xu
Jie Liu
Jinming Yu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2024
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-024-02994-0

Other articles of this Issue 1/2024

Journal of Experimental & Clinical Cancer Research 1/2024 Go to the issue

Research

LncRNA AL139294.1 can be transported by extracellular vesicles to promote the oncogenic behaviour of recipient cells through activation of the Wnt and NF-κB2 pathways in non-small-cell lung cancer

Research

IL6-STAT3-C/EBPβ-IL6 positive feedback loop in tumor-associated macrophages promotes the EMT and metastasis of lung adenocarcinoma

Research

PRMT6-mediated transcriptional activation of ythdf2 promotes glioblastoma migration, invasion, and emt via the wnt–β-catenin pathway

Research

The localization, origin, and impact of platelets in the tumor microenvironment are tumor type-dependent

Correction

Correction: RNA-binding protein RPS7 promotes hepatocellular carcinoma progression via LOXL2-dependent activation of ITGB1/FAK/SRC signaling

Research

CDKL1 potentiates the antitumor efficacy of radioimmunotherapy by binding to transcription factor YBX1 and blocking PD-L1 expression in lung cancer

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits